Once-weekly semaglutide 7·[amount hidden] in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

For the Bulgarian, Hungarian and Polish translations of the abstract see Supplementary Materials section.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Semaglutide, giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

STEP UP T2D was a randomised, phase 3b, double-blind controlled, three-arm, parallel-group trial conducted at 68 hospitals, specialist clinics, and medical centres in Bulgaria, Canada, Hungary, Poland, Portugal, Slovakia, South Africa, and the USA.

This trial is registered with ClinicalTrials.gov (NCT05649137) and is now closed and completed.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Obesity, Weight Loss, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists and Semaglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Semaglutide compound page, all human trials.